Capricor Therapeutics (CAPR) announced that a Type A meeting with the U.S. Food and Drug Administration, FDA, has been scheduled to discuss the regulatory path for its Biologics License Application, BLA, for Deramiocel, the Company’s lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, DMD.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics call volume above normal and directionally bullish
- Biotech stocks rise following Prasad exit from FDA
- Capricor Therapeutics: Strategic Refinement and Optimism for Deramiocel’s FDA Approval
- Largest borrow rate increases among liquid names
- Capricor’s Trial Data Deception Triggers Major Lawsuit